Domestic API manufacturing facility in India

Make in India for Pharma: Why Domestic API Manufacturing Matters for Global Healthcare

Think of India’s pharma sector, built on decades of domestic API manufacturing, like the world’s premier bakery. For decades it’s churned out the loaves of medicine-the tablets, capsules, and vaccines-that feed health systems across the planet. But there’s one hiccup: these bakers have been buying most of the flour, yeast, and sugar from overseas suppliers.

These ingredients are known as APIs: Active Pharmaceutical Ingredients-the actual chemicals that do the work of making a medicine perform. When you pop an aspirin, the API is the precise molecule that takes the pain away, while the rest of the pill is mostly filler material holding it all together.

The Make in India pharma movement aims to change that paradigm. By beefing up domestic API manufacturing, India is in the process of growing its own ingredients-laying down a robust foundation for global healthcare.

The real price of Global Reliance

Global trade functions best until it doesn’t. As we’ve seen in recent history, border closings, export bans and shipping snags can quickly derail supply chains. When manufacturing plants overseas halt production of basic chemical powders, that sends a ripple effect, stopping the creation of everyday antibiotics and heart medication hundreds or thousands of miles away.

India has historically imported anywhere from 70% to 80% of its APIs for critical medicines from just a few countries. If those pipelines were ever disrupted, the health of millions worldwide would be at risk. This dangerous reality is what has made the transition from the board room to the national level an urgent need to reduce API import dependency.

Building Domestic API Manufacturing Security from the Ground Up

That awareness was the genesis of the Aatmanirbhar Bharat pharmaceuticals initiative, a strategy of long-term self-reliance.

India pharma self-reliance does not mean isolation. It means building security. By producing everything domestically- from basic Key Starting Materials (KSMs) to Active Pharmaceutical Ingredients themselves-India erects a critical barrier against global shocks. It ensures that regardless of whether a pipeline freezes or a route is closed, the flow of life-saving medication never stops.

Domestic API manufacturing chain: KSM to medicine

Policy Fuelling the Shift

Visions require capital, and that’s where the Production Linked Incentive (PLI) scheme comes in. The PLI scheme pharmaceuticals program offers direct financial rewards based on the volume of production.

For years, local manufacturers found it difficult to compete against highly subsidized foreign chemical behemoths. The PLI scheme helps level the playing field by making it economically feasible to establish large-scale automated API production facilities capable of competing on the global stage, both in price and in quality.

Moving from Self-Sufficiency to Export Powerhouse

Beyond securing domestic health, the ambition is for India to become a diversified India pharma export hub.

Many global pharma companies seeking to diversify their risks are turning to Indian facilities for their direct API procurement needs. India is now positioning itself as a competitive, reliable alternative for the international community with its combination of chemical engineering expertise and solid supply chains.

Strengthening the manufacturing bedrock of India leads to a stronger global healthcare system. It means reduced drug shortages at your local pharmacy, more consistent pricing for generic medicines, and a reliable supply chain of critical medications for patients everywhere.

Partner With a Trusted Domestic API Manufacturer

India’s push toward domestic API manufacturing is only as strong as the partners building it. At PYG Lifesciences, we manufacture the API intermediates that go into this self-reliant supply chain-from KSMs to finished intermediates for cardiovascular and anti-diabetic APIs. If your business is looking for a reliable domestic manufacturing partner, get in touch with our team to discuss your requirements.

Frequently Asked Questions (FAQs)

What is the difference between an API and a finished medicine?
+

An API (Active Pharmaceutical Ingredient) is the active component within a medicine that actually treats a health condition. A finished medicine is what you find at a pharmacy-an API that has been combined with inactive substances (binders, fillers, coloring) and formed into a tablet, capsule, or solution for injection.

Why did India lose its self-reliance in APIs?
+

In the 1990s and 2000s, other countries invested heavily in subsidizing their chemical industries, which drastically reduced the cost of manufacturing bulk chemicals. As it became significantly cheaper for Indian pharmaceutical companies to import these ingredients than produce them locally, domestic production languished.

How does Indian manufacturing impact global drug shortages?
+

Concentrating API production in a handful of regions means that a disruption in any of those locations-be it a lockdown, power outage, or geopolitical event-can cause shortages worldwide. Having a strong domestic API manufacturing base serves as a critical backup or secondary source for the global supply chain.